A double-blind controlled pilot study of plasma exchange versus sham apheresis in chronic progressive multiple sclerosis
- PMID: 3884114
- DOI: 10.1017/s0317167100046564
A double-blind controlled pilot study of plasma exchange versus sham apheresis in chronic progressive multiple sclerosis
Abstract
Twenty patients with chronically progressive multiple sclerosis (MS) were randomised in a double-blind controlled study to assess the efficacy of plasma exchange therapy. All patients were immunosuppressed with prednisone and azathioprine and underwent either plasma exchange or sham apheresis. The 10 patients in each group were similar in age, sex, duration of disease and degree of disability. Clinical and laboratory responses were assessed immediately following the course of exchange or sham therapy, and 3 to 6 months later, by individuals blinded to the type of therapy administered. Although modest improvement was suggested on clinical examination in 7 of 10 patients exchanged and 3 of the 10 sham treated group, this was transient and was not accompanied by any change in disability status scores. No differences in abnormal laboratory investigations were demonstrable between the two patient groups following therapy. We conclude that plasma exchange therapy using this protocol is unlikely to be of clinical benefit as an adjunct in the management of chronically progressive M.S.
Similar articles
-
The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group.Lancet. 1991 Feb 23;337(8739):441-6. Lancet. 1991. PMID: 1671468 Clinical Trial.
-
Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis.Neurology. 1989 Sep;39(9):1143-9. doi: 10.1212/wnl.39.9.1143. Neurology. 1989. PMID: 2549450 Clinical Trial.
-
The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial.Neurology. 1994 Jan;44(1):16-20. doi: 10.1212/wnl.44.1.16. Neurology. 1994. PMID: 8290055 Clinical Trial.
-
Mitoxantrone: a review of its use in multiple sclerosis.CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review.
-
Therapeutic apheresis in multiple sclerosis and other central nervous system disorders.Ther Apher. 2000 Aug;4(4):263-70. doi: 10.1046/j.1526-0968.2000.004004263.x. Ther Apher. 2000. PMID: 10975471 Review.
Cited by
-
Evidence-based guideline update: Plasmapheresis in neurologic disorders [RETIRED]: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.Neurology. 2011 Jan 18;76(3):294-300. doi: 10.1212/WNL.0b013e318207b1f6. Neurology. 2011. PMID: 21242498 Free PMC article. Review.
-
Plasma exchange in episodes of severe inflammatory demyelination of the central nervous system. A report of six cases.J Neurol. 2004 Dec;251(12):1515-21. doi: 10.1007/s00415-004-0588-8. J Neurol. 2004. PMID: 15645353
-
B cell depletion attenuates CD27 signaling of T helper cells in multiple sclerosis.Cell Rep Med. 2024 Jan 16;5(1):101351. doi: 10.1016/j.xcrm.2023.101351. Epub 2023 Dec 21. Cell Rep Med. 2024. PMID: 38134930 Free PMC article.
-
Longitudinal analysis of peripheral immune cells in patients with multiple sclerosis treated with anti-CD20 therapy.Ann Clin Transl Neurol. 2024 Oct;11(10):2657-2672. doi: 10.1002/acn3.52182. Epub 2024 Sep 15. Ann Clin Transl Neurol. 2024. PMID: 39279291 Free PMC article.
-
B-cells and humoral immunity in multiple sclerosis. Implications for therapy.Immunol Res. 2008;40(3):224-34. doi: 10.1007/s12026-007-8009-6. Immunol Res. 2008. PMID: 17960498 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical